Cytokinetics (CYTK) PT Lowered to $80 at RBC Capital
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $72.09 -7.46%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
RBC Capital analyst Leonid Timashev lowered the price target on Cytokinetics (NASDAQ: CYTK) to $80.00 (from $82.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial
- Donaldson Company (DCI) PT Raised to $95 at Stifel
- Baird Upgrades Deere (DE) to Outperform
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
